These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26774193)

  • 1. Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung.
    Righi L; Vatrano S; Di Nicolantonio F; Massa F; Rossi G; Cavazza A; Volante M; Votta A; Izzo S; Lo Iacono M; Ardissone F; Di Maio M; Novello S; Scagliotti GV; Papotti M
    J Thorac Oncol; 2016 Apr; 11(4):504-15. PubMed ID: 26774193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
    Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
    J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.
    Kadota K; Yeh YC; D'Angelo SP; Moreira AL; Kuk D; Sima CS; Riely GJ; Arcila ME; Kris MG; Rusch VW; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2014 Aug; 38(8):1118-27. PubMed ID: 25029118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucinous micropapillary pattern in lung adenocarcinomas: a unique histology with genetic correlates.
    Kamata T; Yoshida A; Shiraishi K; Furuta K; Kosuge T; Watanabe S; Asamura H; Tsuta K
    Histopathology; 2016 Feb; 68(3):356-66. PubMed ID: 26109197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation Profile of Resected
    Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
    Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.
    Pareja F; Crapanzano JP; Mansukhani MM; Bulman WA; Saqi A
    Cancer Cytopathol; 2015 Mar; 123(3):162-70. PubMed ID: 25557162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
    Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
    Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
    J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation.
    Ichinokawa H; Ishii G; Nagai K; Kawase A; Yoshida J; Nishimura M; Hishida T; Ogasawara N; Tsuchihara K; Ochiai A
    Hum Pathol; 2013 Dec; 44(12):2636-42. PubMed ID: 24119562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma].
    Wang K; Gong H; Li X; Yang Z; Cao P; Wand C; Jiang Y; Wang H; Wang Y; Zhang G
    Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):170-4. PubMed ID: 26268750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological features of lung adenocarcinoma with KRAS mutations.
    Kakegawa S; Shimizu K; Sugano M; Miyamae Y; Kaira K; Araki T; Nakano T; Kamiyoshihara M; Kawashima O; Takeyoshi I
    Cancer; 2011 Sep; 117(18):4257-66. PubMed ID: 21387273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma.
    Wakejima R; Inamura K; Ninomiya H; Nagano H; Mun M; Okumura S; Okubo K; Ishikawa Y
    Pathol Int; 2020 Feb; 70(2):72-83. PubMed ID: 31859434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
    Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
    J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.
    Yoshioka Y; Togashi Y; Chikugo T; Kogita A; Taguri M; Terashima M; Mizukami T; Hayashi H; Sakai K; de Velasco MA; Tomida S; Fujita Y; Tokoro T; Ito A; Okuno K; Nishio K
    Cancer; 2015 Dec; 121(24):4359-68. PubMed ID: 26488212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.